Efficient Protection of Mice from Influenza A/H1N1pdm09 Virus Challenge Infection Via High Avidity Serum Antibodies Induced by Booster Immunizations with Inactivated Whole Virus Vaccine

Overview

Journal Heliyon

Specialty Social Sciences

Date 2019 Jan 10

PMID 30623129

Citations 3

Authors

Kayoko Sato

Yoshimasa Takahashi

Yu Adachi

Hideki Asanuma

Manabu Ato

Masato Tashiro

Shigeyuki Itamura

Affiliations

Soon will be listed here.

Abstract

The immunogenicities of inactivated whole and split virus vaccines derived from influenza A/H1N1pdm09 virus were compared in a mouse model. We demonstrated the unique properties of whole virus vaccine boosters on the serum memory antibody response in mice. Consistent with previous studies, booster immunization with either whole or split virus vaccines of A/H1N1pdm09 virus produced comparable titers of serum antibodies with hemagglutination inhibition and virus-neutralizing activities. However, superior protection against the challenge infection was unexpectedly observed in mice primed and boosted with whole virus vaccines compared with those treated with split virus vaccines, despite similar levels of antibody titers in each group. Immune serum antibodies were shown to be primarily responsible for this protection via passive transfer experiments of immune serum antibodies to naive recipient mice. Moreover, this protection correlated with elevated affinity maturation of the antibodies. Thus, booster immunization with whole virus vaccines elicited a robust serum antibody response with high avidity to the virus, which was not measurable via conventional serological assays.

Citing Articles

Synthesis and Optimization of Next-Generation Low-Molecular-Weight Pentablock Copolymer Nanoadjuvants.

Siddoway A, White B, Narasimhan B, Mallapragada S Vaccines (Basel). 2023; 11(10).

PMID: 37896975 PMC: 10611236. DOI: 10.3390/vaccines11101572.

SARS-CoV-2 IgG Spike antibody levels and avidity in natural infection or following vaccination with mRNA-1273 or BNT162b2 vaccines.

Hickey T, Kemp T, Bullock J, Bouk A, Metz J, Neish A Hum Vaccin Immunother. 2023; 19(2):2215677.

PMID: 37264688 PMC: 10305493. DOI: 10.1080/21645515.2023.2215677.

The Potential of Neuraminidase as an Antigen for Nasal Vaccines To Increase Cross-Protection against Influenza Viruses.

Kawai A, Yamamoto Y, Nogimori T, Takeshita K, Yamamoto T, Yoshioka Y J Virol. 2021; 95(20):e0118021.

PMID: 34379511 PMC: 8475506. DOI: 10.1128/JVI.01180-21.

References

Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T . Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell. 2000; 102(5):553-63. DOI: 10.1016/s0092-8674(00)00078-7. View

Feng J, Mozdzanowska K, Gerhard W . Complement component C1q enhances the biological activity of influenza virus hemagglutinin-specific antibodies depending on their fine antigen specificity and heavy-chain isotype. J Virol. 2002; 76(3):1369-78. PMC: 135831. DOI: 10.1128/jvi.76.3.1369-1378.2002. View

Harada Y, Muramatsu M, Shibata T, Honjo T, Kuroda K . Unmutated immunoglobulin M can protect mice from death by influenza virus infection. J Exp Med. 2003; 197(12):1779-85. PMC: 2193959. DOI: 10.1084/jem.20021457. View

Polack F, Hoffman S, Crujeiras G, Griffin D . A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles. Nat Med. 2003; 9(9):1209-13. DOI: 10.1038/nm918. View

DAVENPORT F, HENNESSY A, BRANDON F, Webster R, Barrett Jr C, Lease G . COMPARISONS OF SEROLOGIC AND FEBRILE RESPONSES IN HUMANS TO VACCINATION WITH INFLUENZA A VIRUSES OR THEIR HEMAGGLUTININS. J Lab Clin Med. 1964; 63:5-13. View

Bender B, Small Jr P . Influenza: pathogenesis and host defense. Semin Respir Infect. 1992; 7(1):38-45. View

Delore V, Salamand C, Marsh G, Arnoux S, Pepin S, Saliou P . Long-term clinical trial safety experience with the inactivated split influenza vaccine, Vaxigrip. Vaccine. 2005; 24(10):1586-92. DOI: 10.1016/j.vaccine.2005.10.008. View

Asanuma H, Matsumoto-Takasaki A, Suzuki Y, Tamura S, Sata T, Kusada Y . Influenza PR8 HA-specific Fab fragments produced by phage display methods. Biochem Biophys Res Commun. 2007; 366(2):445-9. DOI: 10.1016/j.bbrc.2007.11.135. View

Geeraedts F, Goutagny N, Hornung V, Severa M, de Haan A, Pool J . Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling. PLoS Pathog. 2008; 4(8):e1000138. PMC: 2516931. DOI: 10.1371/journal.ppat.1000138. View

10.

Delgado M, Coviello S, Monsalvo A, Melendi G, Hernandez J, Batalle J . Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med. 2008; 15(1):34-41. PMC: 2987729. DOI: 10.1038/nm.1894. View

11.

Takahashi Y, Hasegawa H, Hara Y, Ato M, Ninomiya A, Takagi H . Protective immunity afforded by inactivated H5N1 (NIBRG-14) vaccine requires antibodies against both hemagglutinin and neuraminidase in mice. J Infect Dis. 2009; 199(11):1629-37. DOI: 10.1086/598954. View

12.

Ikeno D, Kimachi K, Kudo Y, Goto S, Itamura S, Odagiri T . A prime-boost vaccination of mice with heterologous H5N1 strains. Vaccine. 2009; 27(23):3121-5. DOI: 10.1016/j.vaccine.2009.01.007. View

13.

Koyama S, Aoshi T, Tanimoto T, Kumagai Y, Kobiyama K, Tougan T . Plasmacytoid dendritic cells delineate immunogenicity of influenza vaccine subtypes. Sci Transl Med. 2010; 2(25):25ra24. DOI: 10.1126/scitranslmed.3000759. View

14.

Monsalvo A, Batalle J, Lopez M, Krause J, Klemenc J, Hernandez J . Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes. Nat Med. 2010; 17(2):195-9. PMC: 3034774. DOI: 10.1038/nm.2262. View

15.

Harada Y, Ninomiya-Mori A, Takahashi Y, Shirakura M, Kishida N, Kageyama T . Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice. Vaccine. 2011; 29(46):8330-7. DOI: 10.1016/j.vaccine.2011.08.091. View

16.

Cox R . Correlates of protection to influenza virus, where do we go from here?. Hum Vaccin Immunother. 2013; 9(2):405-8. PMC: 3859764. DOI: 10.4161/hv.22908. View

17.

Jegaskanda S, Job E, Kramski M, Laurie K, Isitman G, De Rose R . Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. J Immunol. 2013; 190(4):1837-48. DOI: 10.4049/jimmunol.1201574. View

18.

Ato M, Takahashi Y, Fujii H, Hashimoto S, Kaji T, Itamura S . Influenza A whole virion vaccine induces a rapid reduction of peripheral blood leukocytes via interferon-α-dependent apoptosis. Vaccine. 2013; 31(17):2184-90. DOI: 10.1016/j.vaccine.2013.02.016. View

19.

Barr I, Russell C, Besselaar T, Cox N, Daniels R, Donis R . WHO recommendations for the viruses used in the 2013-2014 Northern Hemisphere influenza vaccine: Epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from October 2012 to January.... Vaccine. 2014; 32(37):4713-25. DOI: 10.1016/j.vaccine.2014.02.014. View

20.

Patel M, Shirey K, Pletneva L, Boukhvalova M, Garzino-Demo A, Vogel S . Novel drugs targeting Toll-like receptors for antiviral therapy. Future Virol. 2015; 9(9):811-829. PMC: 4303062. DOI: 10.2217/fvl.14.70. View